Scanning through the pain: Ergonomic considerations for performing echocardiography of animals

Work-related musculoskeletal disorders (MSD) are a common problem among sonographers, with prevalence in human sonographers of 80–90%. However, this problem appears to be largely neglected in the veterinary literature. Awareness of MSDs, ergonomic redesign, workplace management, and physical self-care are components to reducing the risk of developing MSDs. Work-place redesign and alterations in work flow management are discussed, and a template for a more ergonomically favorable echocardiogram table is provided.     

The role of animals in our perception of people

Objective evidence is beginning to confirm the popular belief that people are often judged by the way they interact with animals. This phenomenon is reviewed in the context of social and cognitive psychology and suggestions are offered for future research.     

Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment

Under the 1876 Cruelty to Animals Act it is necessary to recognise pain so that an assessment may be made to determine if it is 'an experiment calculated to give pain' and 'to prevent the animal feeling pain'. Under the conditions of the licence it is also necessary to recognise 'severe pain which is likely to endure' and 'suffering considerable pain'. In the White Paper May 1983 (Command 8883) it is stated that: 'in the application of controls the concept of pain should be applied in a wide sense' and 'the Home Secretary's practice has been to interpret the concept of pain to include disease, other disturbances of normal health, adverse change in physiology, discomfort and distress'. The draft European Convention for the Protection of Vertebrate Animals used for Experimental and other Purposes, aims to control, subject to specific exceptions, any experimental or other scientific procedure which 'may cause pain, suffering, distress or lasting harm'. (The White Paper states that UK control will be stricter than the Council of Europe proposals.) Thus, there is a considerable onus on the experimenter to recognise pain (not to define it) and to alleviate it. It is intended that this article should be of help, not only to newcomers inexperienced in the recognition of pain, but also possibly to those relatively experienced workers who may be called upon to evaluate the pain involved in a new model or an individual animal.(ABSTRACT TRUNCATED AT 250 WORDS)     

Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals

Endocannabinoids have analgesic/anti-inflammatory properties. The biology of endocannabinoids, their receptors, signalling mechanisms and role in the regulation of physiological processes have been extensively reviewed. This review focuses on the role of palmitoylethanolamide (PEA), an endogenous fatty acid amide analogue of the endocannabinoid anandamide, in tissue protective mechanisms. PEA was first identified almost five decades ago in lipid extracts of various natural products, and its anti-inflammatory and antinociceptive effects were established later. Evidence exists that PEA is synthesised during inflammation and tissue damage and a number of beneficial effects, including the relief of inflammation and pruritus, have been shown to be useful in the control of neurogenic and neuropathic pain. The postulated hypotheses as to the mode of action of PEA include a possible local autacoid-like mediator activity regulating mast-cell activity and putative activation of cannabinoids and vanilloid TRPV1 receptors via "entourage" effects. The large number of scientific investigations into the effects of PEA and PEA-related compounds has given rise to new therapeutic opportunities. In spite of the multitude of therapies currently employed to control inflammation, pain, pruritus and tissue damage, the possibility of using a natural compound, such as PEA to manipulate endogenous protective mechanisms may be considered a beneficial novel therapeutic strategy in veterinary medicine.     

Pythiosis, lagenidiosis, and zygomycosis in small animals.

Pythiosis, lagenidiosis, and zygomycosis affect animals living in temperate, tropical, and subtropical climates, and these diseases are often fatal. Although Pythium insidiosum, Conidiobolus species, and Basidiobolus species have been recognized as pathogens for several years, members of the genus Lagenidium have been identified as a cause of oomycosis in dogs only recently. Pythiosis, lagenidiosis, and zygomycosis share similar clinical and histologic characteristics, making them difficult to distinguish from one another; however, distinguishing between these pathogens is important because of differences in epidemiology, choice and duration of therapy, and prognosis.     

Pain mechanisms and their implication for the management of pain in farm and companion animals

Over the last two decades there has been a dramatic increase in the literature relating to the mechanisms and management of pain in domestic animals. Understanding the mechanisms of pain is crucial for its effective management. This review highlights the current understanding of the neurophysiology of nociception and the plastic changes involved in chronic pain states. Additionally, we describe a range of novel molecules and pathways that offer opportunities for the development of mechanism-based analgesic therapies. Pain management in animals is limited by pain assessment which remains highly subjective, with clinicians relying on indirect measures of pain, using rating scales and (less frequently) quantifiable physiological and behavioural parameters. The need for a systematic approach which would assess different pain components is well justified. Species-specific issues on pain assessment and management in mammalian companion and farm animals are addressed in the later part of this review.